CUPR Cuprina Holdings (Cayman) Limited
Financings ·
Cuprina closed the sale of 648,373 more Class A shares at $1.15 after the underwriter exercised its over-allotment option in full. Total gross proceeds reached about $5,716,491, and R. F. Lafferty & Co., Inc. was the sole book-running manager.
Cuprina said Nasdaq staff told its hearings department the bid price shortfall was cured, and a July 7, 2026 panel hearing was cancelled. The release does not say what moved the share price, and year-end cash was $2.4 million against cash used in operations of $7.1 million.
Cuprina holders approved a share consolidation, raised Class B votes from 10 to 100 per share and allowed share issues of 20% or more of Class A shares. About 2.79% of the Class A votes were represented at the meeting.
The Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period.
Cuprina Holdings (Cayman) Limited operates mainly through its Singapore subsidiary, Cuprina Pte. Ltd., as a biomedical and biotechnology company. It develops and commercializes products for the management of chronic wounds and also operates in the health and beauty sector. Its commercial line, MEDIFLY, consists of medical grade sterile blowfly larvae bio-dressings used as a biological debridement tool in Maggot Debridement Therapy. Its pipeline includes three lines of chronic wound care products: collagen dressings made from bullfrog collagen under an exclusive license from NTU, iodine-based topical antiseptic products distributed under a joint venture with Aiodine Laboratory Pte. Ltd., and products using medical leeches. The company expects these to be developed over 2026 and 2027 and to become commercially available subject to regulatory approval. MEDIFLY is sold mainly in Singapore and, since March 2023, in Hong Kong, and its customers are mainly public and private hospitals and clinics in Singapore. It also sells cosmeceutical products introduced in 2023 and plans to expand into the Middle East, including the Gulf Cooperation Council states, and mainland China.
| Product or program | What it is | Stage |
|---|---|---|
| MEDIFLY | Medical grade sterile blowfly larvae bio-dressings for chronic wound debridement | commercialized |
| Bullfrog collagen dressings | Collagen sponges, particles and hydrogels for chronic wounds, under an NTU license | in development, expected commercially available 2026 and 2027 subject to regulatory approval |
| Iodine-based antiseptic products | Iodine-based wound care and topical antiseptic products, distributed through a joint venture | in development, expected commercially available 2026 and 2027 subject to regulatory approval |
| Medical leech products | Products utilizing medical leeches for wound treatment | in development, expected commercially available 2026 and 2027 subject to regulatory approval |
| Cosmeceutical products | Hydrating balm, muscle energy cream and pain relief muscle patch introduced in 2023 | commercialized |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $38,789 | $35,522 |
| Research and development | $176,385 | $177,433 |
| Net income (loss) | -$3.6 million | -$1.1 million |
| Cash from operations | -$7.1 million | -$908,609 |
| Cash and equivalents | $2.4 million | $85,622 |
Our latest story on this, dated Sep 29, 2026: "Cuprina closes over-allotment of 648,373 shares at $1.15, raising offering to about $5,716,491". The story links the filing or release it is based on. Read the story.
Cuprina Holdings (Cayman) Limited trades under the ticker CUPR on NASDAQ.
Cuprina Holdings (Cayman) Limited is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cuprina Holdings (Cayman) Limited is 1995704. Its filings are on SEC EDGAR.
7,365,000 shares as of 2026-04-27, per the cover page of its 20-F filed 2026-04-27.
Our directory records Cuprina Holdings (Cayman) Limited under Singapore.
Our directory classifies Cuprina Holdings (Cayman) Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cuprina Holdings (Cayman) Limited is KYG2592E1109.
aibio.space lists Cuprina Holdings (Cayman) Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Cuprina Holdings (Cayman) Limited operates mainly through its Singapore subsidiary, Cuprina Pte. Ltd., as a biomedical and biotechnology company.
MEDIFLY: Medical grade sterile blowfly larvae bio-dressings for chronic wound debridement Stage: commercialized.
Bullfrog collagen dressings: Collagen sponges, particles and hydrogels for chronic wounds, under an NTU license Stage: in development, expected commercially available 2026 and 2027 subject to regulatory approval.
$38,789 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Cuprina Holdings (Cayman) Limited reported a net loss of $3.6 million for the fiscal year ended Dec 31, 2025, and used $7.1 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Reported a financing. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio